Levo-M Tablet is a combination medication containing Levocetirizine 5mg and Montelukast 10mg, indicated for the management of allergic rhinitis and chronic asthma. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms such as sneezing, rhinorrhea, nasal itching, and urticaria associated with allergic conditions. Montelukast, a leukotriene receptor antagonist, blocks the action of cysteinyl leukotrienes, which are inflammatory mediators involved in bronchoconstriction, mucus production, and airway edema. The synergistic effect of these agents provides comprehensive relief by addressing both histamine-mediated and leukotriene-mediated pathways. Levo-M is commonly prescribed for patients with seasonal or perennial allergic rhinitis and for the prophylaxis and chronic treatment of asthma to improve pulmonary function and reduce exacerbations. The usual dosage is one tablet once daily, preferably in the evening, with or without food. Caution is advised in patients with hepatic impairment, and it is contraindicated in individuals with known hypersensitivity to either component. Adverse effects are generally mild and may include headache, fatigue, dry mouth, or gastrointestinal disturbances. Levo-M Tablet should be used under medical supervision to ensure optimal therapeutic outcomes and minimize potential risks.